PharmaCyte Biotech (PMCB) CEO nets 316,250 shares after tax withholding

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. reported insider equity activity by CEO, President and Director Joshua N. Silverman on 12/12/2025. He acquired 575,000 shares of common stock at $0, increasing his direct holdings.

On the same day, 258,750 shares were disposed of at $1.02 to satisfy the tax liability upon vesting of restricted stock units, and this withholding did not involve an open-market sale. After these transactions, Silverman beneficially owned 316,250 shares directly and 50,000 shares indirectly through JNS Holdings Group LLC.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverman Joshua

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NV 89169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		575,000	A	$0	575,000	D
Common Stock	12/12/2025		F		258,750(1)	D	$1.02	316,250	D
Common Stock								50,000	I	JNS Holdings Group LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

	/s/ Joshua N. Silverman	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PMCB disclose on 12/12/2025?

On 12/12/2025, PharmaCyte Biotech CEO, President and Director Joshua N. Silverman acquired 575,000 shares of common stock at $0 and had 258,750 shares disposed of at $1.02 to cover taxes on vested restricted stock units.

How many PharmaCyte Biotech (PMCB) shares did Joshua N. Silverman acquire?

Joshua N. Silverman acquired 575,000 shares of PharmaCyte Biotech common stock on 12/12/2025, reported with transaction code A at a price of $0 per share.

Why were 258,750 PMCB shares shown as disposed of at $1.02?

The 258,750 shares reported as disposed of at $1.02 represent shares withheld by PharmaCyte Biotech to satisfy the tax liability upon vesting of restricted stock units and do not constitute an actual sale or other open-market transaction.

How many PMCB shares does Joshua N. Silverman own after these transactions?

After the reported transactions, Joshua N. Silverman beneficially owned 316,250 PharmaCyte Biotech common shares directly and 50,000 shares indirectly.

Are any of Joshua N. Silverman’s PMCB shares held indirectly?

Yes. Joshua N. Silverman indirectly holds 50,000 PharmaCyte Biotech common shares through JNS Holdings Group LLC, in addition to his direct holdings.

What is Joshua N. Silverman’s role at PharmaCyte Biotech (PMCB)?

Joshua N. Silverman is a Director and serves as CEO and President of PharmaCyte Biotech, Inc., as indicated in the insider report.

Is the 258,750-share PMCB disposal an open-market sale?

No. The 258,750 shares were withheld by the issuer to cover taxes on vested restricted stock units and are explicitly described as not being an open-market sale.